Abiopharma

🔍 CAHILL JOHN T (Director)

Company: COLGATE PALMOLIVE CO (CL)

Report Date: 2026-08-06

Detailed Transactions and Holdings:

• Acquired 4,170 shares of Common Stock at $71.56 per share (Direct)
  Date: 2026-08-06 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,543.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,170 shares of Common Stock at $93.3712 per share (Direct)
  Date: 2026-08-06 | Code: S | equity_swap_involved: 0 | shares_owned_after: 28,373.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-06 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 36,357.00
• Sold 4,170 shares of Stock Option (Right to Buy) at $71.56 per share (Derivative)
  Date: 2026-08-06 | Code: M | Expires: 2027-05-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4

Footnotes:

• F1: Exercise of stock options awarded under the issuer's incentive compensation plan.
• F2: Sale of shares with a portion of the proceeds delivered to the issuer for payment of the exercise price of options under the issuer's incentive compensation plan.
• F3: Weighted average price, as these shares were sold in multiple transactions at prices ranging from $93.3712 to $93.39, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, additional information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Option became exercisable in equal annual installments over three years beginning on the first anniversary of the May 13, 2019 grant date.